1. Home
  2. CERO vs POAI Comparison

CERO vs POAI Comparison

Compare CERO & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CERO
  • POAI
  • Stock Information
  • Founded
  • CERO 2017
  • POAI 2002
  • Country
  • CERO United States
  • POAI United States
  • Employees
  • CERO N/A
  • POAI N/A
  • Industry
  • CERO
  • POAI Industrial Specialties
  • Sector
  • CERO
  • POAI Health Care
  • Exchange
  • CERO Nasdaq
  • POAI Nasdaq
  • Market Cap
  • CERO 8.4M
  • POAI 9.7M
  • IPO Year
  • CERO N/A
  • POAI N/A
  • Fundamental
  • Price
  • CERO $1.80
  • POAI $1.48
  • Analyst Decision
  • CERO
  • POAI Hold
  • Analyst Count
  • CERO 0
  • POAI 1
  • Target Price
  • CERO N/A
  • POAI N/A
  • AVG Volume (30 Days)
  • CERO 742.5K
  • POAI 2.8M
  • Earning Date
  • CERO 02-24-2025
  • POAI 03-27-2025
  • Dividend Yield
  • CERO N/A
  • POAI N/A
  • EPS Growth
  • CERO N/A
  • POAI N/A
  • EPS
  • CERO N/A
  • POAI N/A
  • Revenue
  • CERO N/A
  • POAI $1,484,223.00
  • Revenue This Year
  • CERO N/A
  • POAI N/A
  • Revenue Next Year
  • CERO N/A
  • POAI $569.48
  • P/E Ratio
  • CERO N/A
  • POAI N/A
  • Revenue Growth
  • CERO N/A
  • POAI N/A
  • 52 Week Low
  • CERO $1.70
  • POAI $0.55
  • 52 Week High
  • CERO $1,238.00
  • POAI $3.76
  • Technical
  • Relative Strength Index (RSI)
  • CERO 32.70
  • POAI 56.75
  • Support Level
  • CERO $1.70
  • POAI $1.37
  • Resistance Level
  • CERO $2.22
  • POAI $1.58
  • Average True Range (ATR)
  • CERO 0.31
  • POAI 0.12
  • MACD
  • CERO 0.26
  • POAI -0.02
  • Stochastic Oscillator
  • CERO 6.76
  • POAI 48.39

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

About POAI Predictive Oncology Inc.

Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.

Share on Social Networks: